Courses of oral corticosteroids · patients with chronic obstructive pulmonary disease
Self‐management interventions including action plans for exacerbations showed no clear difference in courses of oral steroids compared with usual care (low certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide leads to lower number of participants with exacerbations requiring steroids,… compared with placebo (high certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Umeclidinium bromide probably leads to higher quality of life: number of participants with ≥ 4 units improvement… compared with placebo (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Hospitalisations due to COPD exacerbations · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in number of participants with hospital admissions due to COPD… compared with placebo (low certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Umeclidinium bromide leads to higher number of participants with ≥ 1 unit improvement in TDI focal score compared with placebo (high certainty).
1 finding from 1 review
Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 % predicted: relative change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Units SGRQ at end of · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change from baseline in lung function parameters other than FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Six‐minute walk distance · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events at end of · patients with chronic obstructive pulmonary disease
Airway bypass stents showed no clear difference in adverse events at end of compared with control (moderate certainty).
1 finding from 1 review
Cost‐effectiveness · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: relative change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Mortality at end of · patients with chronic obstructive pulmonary disease
Endobronchial coils showed no clear difference in mortality at end of compared with control (moderate certainty).
1 finding from 1 review
Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change from baseline in lung function parameters other than FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Meters change from baseline in 6MWD · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Mortality at end of · patients with chronic obstructive pulmonary disease
AeriSeal showed no clear difference in mortality at end of compared with control (low certainty).
1 finding from 1 review